Please login to the form below

Not currently logged in
Email:
Password:

EMA's Dr Stella Blackburn joins Quintiles

Takes up global head of risk management post
Quintiles EMA Stella Blackburn

Quintiles has appointed Dr Stella Blackburn as vice president and global head of risk management for its real world and late phase research group.  

The development and commercial services group said Dr Blackburn's new role would see her assist with areas such as the interpretation of pharmacovigilance legislation and ensuring regulatory compliance.  

They are key areas for Dr Blackburn, who joins Quintiles from European medicines regulator the EMA where she spent more than 16 years in various roles, most recently as the risk management development and scientific lead.  

Cynthia Verst, president, real world and late phase research at Quintiles, said: “Stella's experience developing innovative risk management solutions is a tremendous addition to our team. Throughout her career, Stella has forged cross-sector partnerships to develop comprehensive risk management policies and processes designed to protect patients and advance clinical research worldwide.”  

In her new role Dr Blackburn will be responsible for leading the group's risk management efforts in the US, EU, Australia and Canada.  

She said: “Together with my colleagues at Quintiles, I aim to provide best-in-class solutions for real-world and late phase evidence development across the global healthcare system and to further develop risk management practices to benefit patients throughout the world.”

Before joining the EMA, Dr Blackburn worked in hospital medicine and also spent more than 11 years in the pharmaceutical industry in a variety of leadership roles.

28th March 2014

From: Research, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics